This Week in Biotech

The buddy system works well for three companies this week while three others take a dive followin...

Avoid This Biotech Stock

Our investing community's latest prime pick to Avoid -- Somaxon Pharmaceuticals.

Scanning 4 Biotechs

Some of these companies may have good news to report in the fourth quarter.

Neurocrine's Big Headache

Another clinical trial means a steep drop in share price, but the company's not dead yet.